[1]Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease[J]. Nat Rev Clin Oncol, 2016, 13: 674-690. [2]Harbeck N, Gnant M. Breast cancer[J]. Lancet, 2017, 389: 1134-1150. [3]Jiagge E, Chitale D, Newman LA. Triple-negative breast cancer, stem cells, and african ancestry[J]. Am J Pathol, 2018, 188: 271-279. [4]Denkert C, Liedtke C, Tutt A, et al. Molecular altera-tions in triple-negative breast cancer-the road to new treatment strategies[J]. Lancet, 2017, 389: 2430-2442. [5]Johnson SF, Cruz C, Greifenberg AK, et al. CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer[J]. Cell Rep, 2016, 17: 2367-2381. [6]Okuma HS, Yonemori K. BRCA gene mutations and poly(ADP-Ribose) polymerase inhibitors in triple-negative breast cancer[J]. Adv Exp Med Biol, 2017, 1026:271-286. [7]Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens[J]. Nature, 2014, 515: 577-581. [8]Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy[J]. Nat Rev Cancer, 2016, 16: 275-287. [9]Boehm U, Klamp T, Groot M, et al. Cellular responses to interferon-gamma[J]. Annu Rev Immunol, 1997, 15:749-795. [10]Zaidi MR, Merlino G. The two faces of interferon-gamma in cancer[J]. Clin Cancer Res, 2011, 17: 6118-6124. [11]Kursunel MA, Esendagli G. The untold story of IFN-gamma in cancer biology[J]. Cytokine Growth Factor Rev, 2016, 31:73-81. [12]Liu Y, Liang X, Yin X, et al. Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-gamma-induced immunologic dormancy of tumor-repopulating cells[J]. Nat Commun, 2017, 8:15207-15219. [13]Kiyozumi Y, Baba Y, Okadome K, et al. IDO1 expres-sion is associated with immune tolerance and poor progno-sis in patients with surgically resected esophageal cancer[J]. Ann Surg, 2019, 269: 1101-1108. [14]Liu Y, Lv J, Liu J, et al. STAT3/p53 pathway activation disrupts IFN-beta-induced dormancy in tumor-repopulating cells[J]. J Clin Invest, 2018, 128: 1057-1073. [15]Liu Y, Liang X, Dong W, et al. Tumor-repopulating cells induce PD-1 expression in CD8(+) T cells by transferring kynurenine and AhR activation[J]. Cancer Cell, 2018, 33: 480-497. |